{"page":{"totalFilteredElements":66},"studies":[{"active":true,"description":"<div>A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator&#8217;s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge</div>","eudractNumber":"2024-517422-25","id":11018,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-23T09:38:08+02:00","shortTitle":"BMS CA071-1000","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator&#8217;s Choice in Participants with Relapsed/Refractory Follicular Lymphoma</div><div>(GOLSEEK-4)</div>","eudractNumber":"2024-519152-82","id":11182,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06911502","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-24T08:34:34+02:00","shortTitle":"BMS CA0731003 GOLSEEK-4","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Liverage<sup>TM</sup> - A randomised, double-blind, placebo-controlled, multicentre, phase III trial evaluating long-term efficacy and safety off survodutide weekly injections in adult particpants with non-cirrhotic, non-alcoholic steatohepatitis - metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis","eudractNumber":"2024-513739-25-00","id":11353,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06632444","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T14:08:51+02:00","shortTitle":"Boehringer Ingelheim 1404-0044","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"LiverageTM&#160;- A&#160;phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis-metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis","eudractNumber":"2024-513741-36-00","id":11352,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06632457","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T14:08:12+02:00","shortTitle":"Boehringer Ingelheim 1404-0064","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","eudractNumber":"2025-521281-97-00","id":12069,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07144280","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":null,"shortTitle":"C5851005","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<p style=\"line-height:normal;margin-top:0pt;margin-bottom:0pt;margin-left:0in;\">A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the \nEfficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP \nChemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma<br /></p>","eudractNumber":"2023-510178-15","id":10012,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-10-23T12:23:27+02:00","shortTitle":"CA073-1020 GOLSEEK-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy</div>","eudractNumber":"2024-520154-38","id":10760,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-20T08:47:30+01:00","shortTitle":"CAMELOT - 2 75276617 AML3001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and \nDexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab,&#160; Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell \nTransplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are \nTransplant Eligible","eudractNumber":"2021-003284-10","id":9102,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05257083","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-01T12:33:38+02:00","shortTitle":"CARTITUDE-6, EMN28/68284528MMY3005","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUK&#196;MIE (CLL): CLL-16 STUDIE DER DCLLSG","eudractNumber":"2020-004360-26","id":8660,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT05197192","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-25T12:36:09+02:00","shortTitle":"CLL16","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ \nsmall lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for \nadjustment of treatment duration to improve outcomes","eudractNumber":"2023-510294-34","id":11270,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-11T09:16:03+02:00","shortTitle":"CLL18 / MOIRAI-TRIAL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}